Unknown

Dataset Information

0

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.


ABSTRACT: In the recent years, using genetically modified T cells has been known as a rapid developing therapeutic approach due to the heartwarming results of clinical trials with patients suffering from relapsed or refractory (R/R) hematologic malignancies such as R/R Acute Lymphoblastic Leukemia (R/R ALL). One of these renowned approaches is Chimeric antigen receptors (CARs). CARs are synthetic receptors with the ability to be expressed on the surface of T lymphocytes and are specifically designed to target a tumor-associated antigen (TAA) of interest. CAR-expressing T cells have the capability of proliferating and maintaining their immunological functionality in the recipient body but like any other therapeutic approach, the safety, effectiveness, and specificity enhancement of CAR T cells still lingers in the ambiguity arena. Genetic manipulation methods, expansion protocols, infusion dosage, and conditioning regimens are all among crucial factors which can affect the efficacy of CAR T cell-based cancer therapy. In this article, we discuss the studies that have focused on various aspects that affect the efficacy and persistence of CAR T-cell therapy for ALL treatment and provide a widespread overview regarding the practical approaches capable of elevating the effectiveness and lessening the relative toxicities attributed to it.

SUBMITTER: Hashem Boroojerdi M 

PROVIDER: S-EPMC7549730 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.

Hashem Boroojerdi Mohadese M   Rahbarizadeh Fatemeh F   Safarzadeh Kozani Pouya P   Kamali Elahe E   Safarzadeh Kozani Pooria P  

Medical oncology (Northwood, London, England) 20201012 11


In the recent years, using genetically modified T cells has been known as a rapid developing therapeutic approach due to the heartwarming results of clinical trials with patients suffering from relapsed or refractory (R/R) hematologic malignancies such as R/R Acute Lymphoblastic Leukemia (R/R ALL). One of these renowned approaches is Chimeric antigen receptors (CARs). CARs are synthetic receptors with the ability to be expressed on the surface of T lymphocytes and are specifically designed to ta  ...[more]

Similar Datasets

| S-EPMC7902522 | biostudies-literature
| S-EPMC10786140 | biostudies-literature
| S-EPMC6637939 | biostudies-literature
| S-EPMC3815169 | biostudies-literature
| S-EPMC6627878 | biostudies-literature
| S-EPMC8123476 | biostudies-literature
| S-EPMC2518903 | biostudies-other
| S-EPMC6238377 | biostudies-literature
| S-EPMC6237143 | biostudies-literature
| S-EPMC9395272 | biostudies-literature